Background-Autosomal recessive hypercholesterolemia (ARH) exhibits different responsiveness to statins compared with that in homozygous familial hypercholesterolemia (FH). However, few data exist regarding lipoprotein metabolism of ARH. Therefore, we aimed to clarify lipoprotein metabolism, especially the remnant lipoprotein fractions of ARH before and after statin therapy. Methods and Results-We performed a lipoprotein kinetic study in an ARH patient and 7 normal control subjects, using stable isotope methodology (10 mg/kg of [ 2 H 3 ]-leucine). These studies were performed at baseline and after the 20 mg daily dose of atorvastatin. Tracer/tracee ratio of apolipoprotein B (apoB) was determined by gas chromatography/mass spectrometry and fractional catabolic rates (FCR) were determined by multicompartmental modeling, including remnant lipoprotein fractions. FCR of low-density lipoprotein (LDL) apoB of ARH was significantly lower than those of control subjects (0.109 versus 0.450Ϯ0.122 1/day). In contrast, the direct removal of very-low-density lipoprotein remnant was significantly greater in ARH than those in control subjects (47.5 versus 2Ϯ2%). Interestingly, FCR of LDL apoB in ARH dramatically increased to 0.464 1/day, accompanying reduction of LDL cholesterol levels from 8.63 to 4.22 mmol/L after treatment with atorvastatin of 20 mg/d for 3 months. Conclusions-These results demonstrate that ARH exhibits decreased LDL clearance associated with decreased FCR of LDL apoB and increased clearance for very-low-density lipoprotein remnant. We suggest that increased clearance of remnant lipoprotein fractions could contribute to the great responsiveness to statins, providing new insights into the lipoprotein metabolism of ARH and the novel pharmacological target for LDLRAP1. (Circ Cardiovasc Genet. 2012;5:35-41.) (A.I.). The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
F amilial hypercholesterolemia (FH) is a common inherited disorder of plasma lipoprotein metabolism, characterized by an elevated level of low-density lipoprotein cholesterol (LDL-C), tendon xanthomas, and premature coronary artery disease. 1 Genetic causes of FH involve gene mutations such as LDL receptor (LDLR), apolipoprotein B-100 (apoB-100), and proprotein convertase subtilisin/kexin type 9 (PCSK9). 2 In contrast, there was a report of autosomal recessive inherited cases, who showed elevation of LDL-C, large xanthomas, and premature coronary artery disease typical of homozygous FH but in whom the fibroblasts had normal LDLR function. 3 Subsequently, Garcia et al 4 showed that this disorder was caused by a recessive form of null mutations in the LDLR adaptor protein 1 (LDLRAP1).
Clinical Perspective on p 41
Since then, evidence has been accumulating that it was not linked to mutations in the LDLR gene. 5, 6 The N-terminal domain of LDLRAP1 contains a phosphotyrosine-binding (PTB) domain, which binds to the internalization sequence (FDNPVY) in the cytoplasmic tail of the LDLR. 7 LDLRAP1 protein serves as an adaptor for LDLR endocytosis in the liver and a deficiency in this protein results in the decline of LDL-C catabolism, as seen with homozygous FH. 8 However, ARH differs from homozygous FH in the severity of the clinical phenotype and response to statins, the cause of which still remains unclear. 5 One of the possible mechanisms of great responsiveness to statins was elucidated by a metabolic study using LDLRAP1 knockout mice that showed preserved ability for LDLRdependent VLDL clearance. 9 However, few data exist regarding the metabolic basis of LDLRAP1 in clinical settings, especially, the metabolism of remnant lipoprotein fractions. Therefore, we examined lipoprotein kinetics in the homozygous ARH patient, using a stable isotope methodology with kinetic modeling including several remnant lipoprotein fractions, before and after atorvastatin therapy.
Methods

Study Subjects
This study was approved by the Ethics Committee of Kanazawa University, Suzu General Hospital, for the ARH patient and Jikei University School of Medicine for the control subjects. All study subjects gave their written informed consent to participate. We examined 8 subjects including 1 patient with suspected ARH without any evidence of chronic disease or malignancy and 7 normal control subjects (all men; age, 41Ϯ8 years). All lipid-lowering therapy had been strictly suspended for 3 months until the baseline study. We checked the lipid level of the patient suspected ARH 1 month before the baseline study as well as 1 week before the baseline study to confirm that his cholesterol level was appropriately elevated and reached plateau. Next, we reexamined ARH patient after treatment with atorvastatin of 20 mg/d for 3 months.
Genetic Studies
Genomic DNA was isolated from peripheral blood white blood cells according to standard procedures and was used for PCR. We analyzed the coding regions of LDLR, PCSK9, and LDLRAP1 genes. Primers for the study were as used previously. 10, 11 PCR products were purified by Microcon (Millipore Corp, Bedford, MA) and used as templates for direct sequencing. DNA sequencing was carried out according to the manufacturer's instructions, using a dye terminator method (ABI PRISM 310 Genetic Analyzer (PerkinElmer Biosystems, Waltham, MA).
Biochemical Analysis and LDLR Activity
Serum concentrations of total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) were determined enzymatically. LDL-C concentrations were derived by means of the Friedewald formula. Apolipoprotein E (apoE) phenotype was separated by isoelectric focusing and detected by Western blot with apoE polyclonal antibody (phenotyping apoE IEF system, JOKOH, Tokyo, Japan). Lipoprotein lipase (LPL) mass in postheparin plasma was measured according to the method we previously reported. 12 LDLR activity was measured by 2 methods, both of which used peripheral lymphocytes; The first was commercially available binding assay and the second was our original assay, which was described in detail elsewhere. 13 Briefly, we could measure accurate LDLR activity by using heparin to exclude the overestimation signals only bound at the surfaces of lymphocytes, even in the case with internalization defective type of disease.
Lipoprotein Kinetic Study
After an overnight fast, the study subjects were given a bolus injection (10 mg/kg) of [ 2 H 3 ]-leucine (Cambridge Isotope Laboratories, Woburn, MA). Blood samples were drawn periodically for 48 hours after the bolus injection.
Determination of Isotopic Enrichment
Samples were prepared for GC-MS analysis as reported previously. 14, 15 For detailed determination of isotopic enrichment, please see online-only Data Supplement Method I. Figure 1 shows the multicompartmental model used in this study, which was built using an interactive computer program (SAAM II, version 1.1; SAAM Institute Inc) to determine apoB kinetic parameters. 16, 17 For detailed kinetic modeling, please see online-only Data Supplement Method 2.
Kinetic Modeling
Changes in Lipoprotein Subfractions
Lipoproteins of ARH were separated by the method based on those sizes using HPLC (LipoSEARCH, Skylight Biotech, Akita, Japan). 18 Changes in cholesterol, triglyceride, free cholesterol, and phospholipids in each lipoprotein subfraction was assessed by HPLC. 
Results
Identification of ARH
A 68-year-old Japanese man presented at Kanazawa University Hospital for further examination of his hypercholesterolemia and severe tendon xanthomas (online-only Data Supplement Figure IA and IB). The proband was born to consanguineous parents (first cousins); neither parent had any signs of hypercholesterolemia or xanthomas. Large cutaneous and tendon xanthomas were identified on his fingers and foot, which had developed around 10 years of age. The thickness of his Achilles tendons reached 26 mm (online-only Data Supplement Figure IC ). Initial serum TC and TG concentrations were high: 13.27 mmol/L and 3.39 mmol/L and were decreased to 5 mmol/L and 0.5 mmol/L after statin treatment for 8 years, respectively (online-only Data Supplement Figure  ID Although there was no mutation detected in LDLR and PCSK9 genes, homozygous mutation of an extra cytosine inserted into the region of the LDLRAP1 gene was found (c.606dup, previously described as ins C 599 ) in our proband (online-only Data Supplement Figure II ), which is completely identical to that found in the first Japanese family identified with ARH. 19 An investigation, which extended back over 5 generations, failed to show any relationship between these 2 families, whose geographical origin were completely different. Using genetic analysis, we diagnosed 11 ARH heterozygous subjects and 6 normal subjects in the proband's family ( Figure 2 ). Their lipid data and major clinical findings including the presence of coronary artery disease are listed in the online-only Data Supplement Table. As for LDLR activity, we found extremely accelerated LDLR activity (as much as 160% of normal control subjects) measured by the binding assay, using the measurement of 3,3Ј-dioctadecylindocarbocyanin (DiI)-labeled LDL uptake in blood peripheral lymphocytes (BML, Tokyo, Japan). In contrast, the value measured by our internalization assay using heparin showed that the activity was reduced to 14% of normal control subjects.
Lipoprotein Kinetic Study
At the time of the kinetic study (Table 1) , the ARH patient showed higher serum TC levels (10.26 versus 4.87Ϯ0.58 mmol/L) and higher LDL-C levels (8.63 versus 2.95Ϯ0.49 mmol/L) than those of the control subjects.
The VLDL apoB, IDL apoB, and LDL apoB tracer/tracee ratio curves at baseline and after atorvastatin therapy, as well Table. as those for the mean of the control subjects, are shown in Figure 3 . Kinetic parameter of apoB within each lipoprotein fraction is shown in Production rates (PRs) of the ARH patient of the 3 fractions were within the mean value Ϯ2 SD of those of control subjects. Therefore, the markedly increased concentrations of IDL and LDL apoB were primarily due to the decreased catabolism rate in the ARH patient. Surprisingly, the FCR of LDL apoB significantly increased to within the normal range after statin therapy in the ARH patient (0.109 -0.464 1/day), resulting in a 70% reduction of LDL apoB concentration. This result was completely differ-ent from that seen with homozygous FH, where the FCR of LDL apoB was reported to be unchanged after statin therapy. 20 In addition to the response observed in FCR of LDL apoB, those of VLDL and IDL apoB also increased by the statin therapy in the ARH patient (3.153-7.881 1/day for VLDL, 1.414 -2.525 1/day for IDL).
Remnant Fractions
Next, we investigated detailed metabolic channeling in the ARH patient (the results are summarized in Table 3 ). In the control subjects, the liver primarily secrets VLDL (87.0Ϯ11.0%), most of which (85.5Ϯ18.7%) was, in turn, converted to IDL by lipoprotein-mediated delipidation, thus leaving the VLDL remnant as a minor fraction (12.0Ϯ11.8% of total VLDL mass). Some crucial differences between the ARH patient and the control subjects were noted in VLDL metabolism. In the ARH patient: (1) only half of VLDL was converted to IDL (52.5%); (2) VLDL remnant mass comprised as much as 60.2%, resulting from an alteration in metabolic channeling in favor of the conversion to VLDL remnant (47.5% versus 1.8Ϯ2.1%, ARH versus control, respectively): (3) removal rate of VLDL remnant (k[0,12]) was increased (4.3 1/day) compared with that of the control subjects (1.3Ϯ0.9 1/day); and (4) direct removal of VLDL, including VLDL remnant, was much higher compared with that of the control subjects (47.5% versus 14.5Ϯ18.7%), a finding mirroring the decreased conversion to IDL as noted above. Furthermore, these tendencies were more pronounced after atorvastatin therapy. As shown in the middle panel of Table 3 , most IDL was derived from VLDL and exclusively converted to LDL (97.8Ϯ3.1%) in the control subjects. In the ARH patient, however, about one-quarter of IDL was directly secreted from the liver and more IDL fractions were directed into remnant, again resulting in the increased remnant mass. These tendencies remained unchanged by atorvastatin therapy. Finally, the only notable difference in LDL metabolism was higher direct secretion of LDL with atorvastatin therapy, a finding consistent to higher tracer/tracee ratios during early time points (pink squares with dotted line in Figure 3C ).
Changes in Lipoprotein Subfractions
As shown in online-only Data Supplement Figure III , relatively wide range of apoB-containing lipoproteins, including large VLDL, could be reduced by atorvastatin therapy in all fractions of lipids (cholesterol, triglyceride, free-cholesterol, and phospholipids) in the ARH patient.
Discussion
In this study, we performed an in vivo lipoprotein kinetic study, allowing us to assess detailed metabolic behavior of apoB-containing lipoproteins in ARH. Our results demonstrated that in ARH there existed reduced LDL catabolism, which could be normalized by statin therapy and dramatically increased clearance of VLDL remnant as well as other remnant lipoprotein fractions in spite of the fact that our ARH patient has apoE2 isoform which could cause the disturbance in remnant clearance. 21 These unique metabolism of apoBcontaining lipoprotein fractions, including VLDL and its remnant fractions were completely different from those reported in heterozygous/homozygous FH patients. 17, 22 One of the possible explanations for the paradoxical acceleration of remnant lipoprotein fractions in ARH is the existence of another pathway, which is independent from the FDNPVY internalization for VLDL and its remnants and does not require LDLRAP1 protein. 23 In addition, Altenburg et al 24 demonstrated that deficiency in the molecule which enhanced the affinity between ligands such as VLDL remnant and LDLR could accelerate the internalization of the remnants. This is consistent with the notion that remnants are passed from one cell surface molecule to the other before internalization. 24 If LDLRAP1 served as an anchor between VLDL remnant and LDLR, deficiency in this protein could result in the increased catabolism of VLDL remnant in ARH. Another possibility is that unknown pathways may exist that are inactivated in the presence of LDLRAP1. This hypothesis seems to be supported by the fact that the LDLR can transfer such remnants to an additional receptor for uptake by the liver when its internalization is impaired. These pathways are not always through LDLR, LDLR-related protein (LRP), and heparan sulfate proteoglycan. 25 In contrast to homozygous FH patients, the ARH patient responded to statin therapy by an increasing rate of LDL apoB catabolism, resulting in about 70% reduction of LDL apoB pool size. Statin therapy also modulated LDL synthesis in favor of more direct secretion from the liver (11% at baseline to 16% with the treatment versus a mean of 7% for the control subjects). The rate of LDL catabolism is a function of LDLR activity or/and LDL particle affinity to the LDLR. Thus, our results indicate that atorvastatin upregulate LDLR activity in the absence of LDLRAP1. Another possibility for the increasing rate of LDL apoB catabolism seen in ARH is that directly secreted LDL may have a higher affinity for LDLR compared with LDL-processed delipidation/remodeling. Different ratio of apoB/LDL-C between the ARH patient and the control subjects suggest that different LDL processing occurred through delipidation/remodeling of LDL particles under the condition of the absence of this adaptor protein. We also provide additional information for the impact of atorvastatin on the distribution of lipoprotein subfractions in ARH. Relatively wide range of apoBcontaining lipoproteins, including large VLDL, could be reduced by atorvastatin therapy. This may be explained by the statin-induced upregulation of possible pathway which could accelerate the clearance of remnant lipoprotein fractions in ARH.
As for the dramatic decrease in PR of VLDL apoB under atorvastatin therapy, one of the possible explanations is the upregulated activity of HMG-CoA reductase suggested by the relatively high level of lathosterol at baseline (Table 1) . On 
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the other hand, the increase in the PR of LDL apoB during atorvastatin therapy could be partially explained by the elevation of LPL mass (Table 1 ), in accordance with the previous report. 26 Also, another study has shown that atorvastatin therapy is associated with an increase in LPL activity. 27 These data suggest that atorvastatin treatment may cause an increase in the conversion of VLDL to LDL.
Limitations
Our study has several limitations. First, only 1 ARH patient was included in this study because of the rarity of this disease, making it difficult to compare the results statistically. Also, the age of the control subjects were younger than the ARH patient, although all were male. Second, we did not measure apoE FCR in the ARH patient and thus could not draw any conclusion regarding the possibility of the clearance through VLDL receptor. However, the fact that the ARH patient has apoE2 isoform, which could cause the disturbance in remnant clearance, indicates the less influence of the apoE pathway on the catabolism of these lipoproteins. In this study, as much as 30% increase in HDL-C was achieved through atorvastatin therapy. Another kinetic study targeting apoA-I for the ARH patient may reveal the metabolic aspects about the increase in HDL-C. Finally, it would be worthwhile to compare lipoprotein kinetics of ARH with that of FH directly. Although we cited previously published data on the apoB kinetics in FH patients to discuss the comparison between the kinetics of ARH and FH, further kinetic study comparing ARH and FH directly is needed to confirm this matter.
Conclusion
In summary, the first detailed lipoprotein kinetic study including remnant lipoprotein fractions in ARH before and after statin therapy revealed 2 important aspects of the lipoprotein metabolic basis of this disease. First, FCR of LDL apoB in ARH was decreased by about 76% that of normal control subjects at baseline; however, the catabolic parameter was elevated to normal range after statin therapy (atorvastatin 20 mg). Second, and possibly the major finding from this investigation, is that the clearance of the VLDL remnant as well as other remnant fractions were dramatically increased compared with normal control subjects. We suggest that these results will provide new insights into the lipoprotein metabolism of ARH and the novel pharmacological target for LDLRAP1. 
